Updates: 4/19/18 GWPH hits $143 new high, then sold off holding $134 level, after big move from $105 on cannabis drug for severe epilepsy FDA Advisory go ahead. Biotechs broadly in the red except CRSP up 6.4% and NVCR up 5%. AstraZeneca (AZN) gained US approval for 1st line use of lung cancer drug. Novartis (NVS) shares […]
Updates 4/11/18 Biotechs Holding Above Recent Bottom 4/6/18 FBT up 2.8% over 5 days, up 6% YTD XBI up 1.77% over 5 days, up 2.19% YTD IBB down 0.72% over 5 days, down 3.67% YTD Busted Biotechs Review In our “Busted Biotechs” article we said that the XBI trade at 83-84 would be good, now […]
4/17/18 Latest portfolio changes are working: CELG at $88, XBI at $84. all based on technicals. ========== Busted Biotech Stocks Get No Help From the Overall Market 4/8 Update XBI down 3% on 4/6 and BELOW SMA 20 AT $82.90. Bellwether Mid-Caps red screen-two up stocks CLVS ICPT ; NKTR down 7.48% ! Incyte (INCY) […]
2018 Large Cap Biopharmaceuticals – Performance Compared to ETFs It has been a rough start for large cap biopharmaceutical stocks but the ETFs (FBT) and (XBI) still outperformed the SPY YTD and over 12 months. Most Individual stocks lagged unless you owned Abbvie (ABBV) or Vertex Pharmaceuticals (VRTX). Here are some key takeaways: Buy the worst […]
4/2/18 12:30P Update Biotechs break through 2018 support levels with XBI now needs to hold December lows at $80. IBB at double bottom hit in November/December at $102 level. Watch Mid-Cap list below for sector weakness. ============== Biotech Bull Market Is Intact with Unusual Volatility Biotech Stocks Will Try to Regain Bullish Footing After A […]
Sell-Off Gets Scary–NASDAQ Futures Still Down at 1:30A EDT 3/28 Double Bottom -Double Top on XBI and Testing February Lows at $87 Another Sell-Off=Tuesday Movers 3/27/18 Large Caps % Up-NONE FBT Down 3.23%, IBB Down 2.77% to $105.12, QQQ down 3.24%, XBI down 4.27% Mid-caps % Up -None ========== BIG RALLY-Monday Movers 3/26/18 FBT Up 2.83%, […]
Update-2…3/22 ABBV News Kills Momentum of Biotech Stocks 12:30P EDT Abbvie (ABBV) down 13.5 % on disappointing results on blood cancer drug. The big issue is that the drug was recently acquired for $5.8B from Stemcentrx back in 2016. The Company will not seek accelerated approval for Rova-T in Third-Line treatment of patients with relapsed/refractory small […]
Update-1… 3/19. Close is off the lows for Biotech Indices QQQ gap down to $167.10 also at SMA 50 XBI at SMA 50 bottom of channel at $91.89 XLV at $84 approaching February lows of $81 It is very difficult to find news or trends that can help us navigate this sell-off where macro […]
Update-1 …March 18- Market jittery on potential global trade war, rising interest rate concerns and political risk. Also Sales to U.S. retailers fell 0.1% in February a 3 month slide. Biotechs are in a risk-off mode with a weak tape. Dow down 0.47%, NASDAQ down 0.2%, IBB down 0.98%, XBI down 1.56% Biotechs stocks were red across […]
Update-1 March 10… Broad Rally Continues Through The Week QQQ Up 4.3% IBB up 4.3% XBI up 4.8% Gene Editing Stocks Surge Biotech stocks soared along with the market as fear about interest rates, tariffs and global politics subsided helped considerably by economic sentiment and jobs. Moreover the employment report showed wage gains revised downward […]
PO Box 3701
Manhattan Beach CA 90266
(310) 871-1231
rod@rayno.com
Rod Raynovich is the founder of Raygent Associates, a management consulting firm providing business development and strategic marketing services in the life science and medical device area. He publishes his thoughts and analysis on the biotech industry at www.raygent.com.